Vasoactive Drugs Flashcards
The Autonomic NS
Responsible for the involuntary control of autonomic body functions
Divisions of the Autonomic Nervous System (Sympathetic)
“FIGHT or FLIGHT”
Thoracolumbar outflow
Postganglionic neurotransmitter is Noradrenaline bind Αlpha and Beta receptors
Temperature, glucose, vascular responsiveness, ventilation, cardiac output and GIT
Stress response
Divisions of the Autonomic Nervous System (ParaSympathetic)
“HOMEOSTATIC”
Craniosacral outflow (cranial nerves (3,7,9,10) and sacral (2-3) Postganglionic neurotransmitter is Acetylcholine bind to (cholinergic) Nicotinic and muscarinic receptors
The Stress Response
Series of Neurohumoral responses to optimise the bodily defence mechanisms for short-term survival ….. “fight or flight”
The Stress Response (Neural: HAEMODYNAMIC)
Increased sympathetic outflow
Blood flow
Increased: heart, lungs, brain and muscle (β)
Decreased: GIT, kidney, liver (splanchnic circulation) and skin (α)
The Stress Response (Humoral: HORMONAL)
Defence of blood volume
Increased: aldosterone and ADH - salt and water retention
Mobilisation of glucose stores to supply vital organs with energy
Insulin inhibited
The Adrenal Medulla
Specialised sympathetic ganglion with no postganglionic fibres
Postganglionic fibres are secretory cells
The medulla secretes hormones when stimulated (Noradrenaline (NA) – 70%; Adrenaline (Adr);
Dopamine (DA) – small amount)
Cholinergic Receptors
distribution
All autonomic ganglia (including the adrenal medulla)
All parasympathetic postganglionic nerve terminals
Sympathetic postganglionic nerve terminals in sweat glands (exception!)
Cholinergic Receptors (subtypes)
Nicotinic= At skeletal NMJ and ALL autonomic ganglia (incl adrenal medulla)
Stimulated by nicotine and Ach
Inhibited by Neuromuscular blocking agents
Muscarinic= At parasympathetic postganglionic fibres
Stimulated by muscarine and Ach
Inhibited by atropine, glycopyrrolate
Adrenergic receptors: distribution
Only found at the sympathetic postganglionic nerve terminals
Adrenergic receptors: subtypes
Alphaα1: post-synaptic – smooth muscle vasoconstriction (e.g. blood vessels)
Increases the BP ± reflex bradycardia
α2: pre-synaptic – inhibits further NA release (central) sedation, analgesia, hypotension
Beta:β1: increased contractility, HR, AV node conduction, refractory period, renin secretion and lipolysis
β2: increased skeletal muscle vessel dilatation, bronchial relaxation, uterine relaxation, bladder relaxation, glycogenolysis
Neostigmine: stimulation of PNS
Blocks acetylcholinesterase, therefore natural concentration of Ach increases
This will displace neuromuscular blocking agents (NMBs) and facilitates reversal of these drugs
BUT… this also results in parasympathetic stimulation of muscarinic receptors (which are not blocked by NMBs)
This causes side-effects!
Anticholinergic drugs: muscarinic blockade of the PNS
Blockade inhibits muscarinic effects (e.g. atropine and glycopyrrolate)
Unmasks background effects of sympathetic nervous system
Prevents Side-Effect
Glycopyrroloate: does not cross the blood brain barrier
Sympathomimetics
stimulants
Have β1 effects are termed inotropes as they increase the force of contraction.
Have α1 effects are termed vasopressors as they contract vessels and raise blood pressure
Direct acting: Adrenaline (all alpha and beta) and NA (alpha 1&2 and beta1)are both inotropes and vasopressors
Phenylephrine (only alpha1) is a vasopressor but not an inotrope
Dobutamine is an inotrope
Indirect acting:
Ephedrine
releases NA from sympathetic terminals, as well as direct (α1 β1) effects
α2= Clonidine
Dexmedetomidine
Sedative, analgesic
(Isoprenaline
β1 and 2 effects)
β2= Salbutamol
Bronchodilatation
Uterine relaxation
SNS Blockers
α receptor antagonists (blockers): Occasionally used as antihypertensives but are agents of choice in phaeocromocytoma Phentolamine – α1 and 2 Phenoxybenzamine - α1 (noncompetitive) Prazosin and Doxazosin - α1
β blockers:
All competitive with varying β1 or β2 effects
Bradycardia, antiarrythmics, sedative, lower BP
Decrease cardiac mortality
Bronchospasm in asthmatics
Inhibit gluconeogenesis in liver and lipolysis
Combined α and β antagonists: Labetalol b>a